Annual Product Revenues Up 54%SOUTH ORANGE, NJ - (NewMediaWire) - March 12, 2019 - Nephros, Inc. (OTCQB:NEPH), a commercial stage company that develops and sells high performance liquid purification filters for both medical device and commercial markets, today announced financial results for the three months and full year ended December 31, 2018.Fourth Quarter Financial HighlightsProduct revenue was $1.6 million, up 33% compared to $1.2 million in 2017.Total revenue was $1.6 million, up 24% compared to $1.3 million in 2017.Net loss in the Water Filtration business segment was $272,000, compared to net income of $1,316,000 in 2017.Adjusted EBITDA in the Water Filtration business segment was $136,000, compared to ($71,000) in 2017.Year-End 2018 Financial HighlightsProduct revenue was $5.5 million, up 54% compared to $3.5 million in 2017.Total revenue was $5.7 million, up 50% compared to $3.8 million in 2017.Net loss in the Water Filtration business segment was $2,416,000, compared to net loss of $766,000 in 2017.Adjusted EBITDA in the Water Filtration business segment was ($861,000), compared to ($1,247,000) in 2017.Full Year 2019 Financial GuidanceRevenues of $8.5 to $9.5 million, an increase of 50% to 65% over 2018.Continued gross margins 55% to 60%.Positive Adjusted EBITDA in the Water Filtration business segment.Daron Evans, President and CEO of Nephros stated, “We are very pleased with our 2018 performance, including the continued momentum in our Water Filtration business segment, which met our plan to grow at least 50% and which delivered positive Adjusted EBITDA in the fourth quarter. In addition, at the end of 2018, we expanded our business with the acquisition of Biocon 1, LLC and its Aether brand of water filtration systems. We expect this acquisition to accelerate our overall growth and to expedite our entry into the food service, hospitality, and convenience store markets.”Corporate UpdateHospital Infection Control MarketIn 2018, revenue from the hospital infection control market grew approximately 57% from 2017, driven primarily by increased sales through our strategic distribution partners. We continue to focus on water safety education and patient safety. We moved into our new offices near the Newark airport to assist in launching our “same day” service – routinely shipping orders to customers all over the country in their time of need.“We appreciate the efforts our customers and strategic partners have undertaken over the last few years to increase awareness of waterborne pathogens, and to develop proactive management strategies to reduce the risk of patient infection,” said Shane Sullivan, Vice President of Sales. “We have seen the whole industry increase the number of proactive measures taken to prevent infection from waterborne pathogens. We are proud to provide a suite of products that complement other technologies in a multibarrier approach to infection prevention.”Commercial / Industrial Water Filter MarketAt the end of 2018, we acquired Biocon 1, LLC and Aether Water Systems, LLC (together, “Aether”). The Aether product portfolio includes water filters that improve the taste and odor of water and reduce scale build-up in downstream equipment. Aether products target the food service, hospitality, and convenience store markets. We expect the Aether acquisition to provide accretive growth and have an immediate positive impact on revenues. Additionally, we expect Aether to expedite our entry into multiple large market segments. We believe that enabling Aether to fully leverage our sales, marketing, engineering, and quality infrastructure will enable Aether’s revenue to grow more quickly.“With the additional scale and engineering acumen of Nephros, we believe we will be better able to pursue national accounts and expand our manufacturing capabilities,” said Greg Lucas, President of Aether. “For many years, our products have been performing well in the market and we look forward to accelerating our commercial expansion.”Dialysis Water Filter MarketRevenue from the dialysis water filter market grew by ...

Opportunity to collaborate with industry experts in the biomass conversion to high value product marketMILTON, GA - (NewMediaWire) - March 12, 2019 - Attis Industries Inc. (NASDAQ: ATIS) (the “Company” or “Attis”), a diversified innovation and technology holding company, announced that it will be attending and presenting at the Biorenewable Deployment Consortium (“BDC”) today in Jacksonville, FL.This will be the fourth time that Attis has attended the BDC and the third time as a presenter. Attis is looking forward to providing an update on its various projects and technologies to a very well attended conference that focuses primarily on the valorization of biomass across multiple markets. Attis plans to provide an update on its recently announced planned acquisition of the Sunoco LP corn ethanol plant in Fulton, NY as well as its biorefinery project in Barnesville, GA. The BDC is the perfect opportunity for Attis to discuss its suite of biomass conversion technologies, specific project updates and end product market development. Year after year, the BDC continues to draw some of the industry’s most influential minds with regards to the valorization of biomass and its various constituents. Attis welcomes the opportunity to collaborate with industry experts and looks forward to receiving input and new perspectives from the attendees.“We are always eager to participate in conferences like the Biorenewable Deployment Consortium,” stated Jeff Cosman, Attis Industries CEO. “Conferences like the BDC are a fantastic opportunity to partake in discussions that directly impact one of Attis’ core business segments. The conference format and level of competency of its attendees presents a great chance for Attis to gather alternative perspectives and network with numerous potential customers and partners.”Presenting at the conference will be Attis’ VP of Marketing, Chris Kennedy. Mr. Kennedy is a 15-year veteran of the renewable fuels industry and works closely with senior management on the development of Attis’ various biorefinery projects and end product market development.Attis Industries, Inc. Attis Industries Inc. (NASDAQ: ATIS) is a diversified innovation and technology holding company focused on developing and building businesses that play important roles in the new economy. We strive to encourage our employees to be entrepreneurs focused on innovation and technology. We will remain dynamic, persistent and motivated to our mission of winning. The growth of our company will rely on our integrity and our vision for the future. Today, each of Attis business sectors provide high growth opportunities that collectively account for more than a third of our nation’s GDP. For more information, visit: www.attisind.comForward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “should,” “would” or similar words. You should consider these statements carefully because they discuss our plans, targets, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. These statements are subject to certain risks, uncertainties, and assumptions, including, but not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; the ability of the Company to continue to meet the listing requirements ...

Las Vegas, NV - (NewMediaWire) - March 12, 2019 - Meso Numismatics, Inc. (“Meso Numismatics” or the “Company”) (OTC: MSSV), a technology and numismatic company specializing in the Meso Region, including Central America and the Caribbean, announced that last week, the Company has formally submitted the OTCQB application materials to OTC Markets Group, operator of OTCMarkets.com. Melvin Pereira, President of Meso Numismatics, Inc., stated, “Last Thursday, March 7th, we submitted the OTCQB application materials to be reviewed by the OTC Markets Group, to upgrade the Company to the OTCQB. We expect this application to be approved, and if it is, the Company will trade on a more transparent stock marketplace. This is in addition to making the appropriate filings with the SEC.”The Company already maintains a Verified Company Profile at OTCMarkets.com.While the Company’s application for the OTCQB is pending review, management, with the assistance of its outside counsel, will continue working closely with the OTC Markets Group, to supply any additional information needed for the upgrade. Management will continue to keep shareholders informed of the progress once the Company receives further information from the OTC Markets Group. Upgrading to the OTCQB is expected to improve the Company’s position in the public markets and increase visibility to the investment community.For more information about Meso Numismatics, please visit www.MesoNumismatics.com.About Meso Numismatics, Inc.Meso Numismatics is a numismatic company specializing in the Meso Region, including Central America and the Caribbean. The Company has become the main hub for rare, exquisite, and valuable inventory, not only from the Meso Region but also from around the world. Meso is the only Company in the Central American-Caribbean region that is an on-the-ground registered dealer with the Numismatic Guaranty Company (NGC) and the Paper Money Guaranty (PMG).Meso Numismatics not only boasts an impressive selection of rare inventory, but the Company also has a specialized App for banknote recognition, available on Google Play and the Apple App Store.Meso Numismatics continues its partnership with eBay (https://www.ebay.com/str/mesonumismatics). The Company continues to partner with some of the largest auction houses in the world for the sale of the Company’s rarer inventory.To view the Award-Winning PMG Set of Meso Numismatics, please visit www.mesopmgset.com.For more information, please visit www.MesoNumismatics.com or call (800) 889-9509 for personalized customer service.Forward Looking Statements: Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "intends," "plans," "believes" and "projects") may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking ...

CUPERTINO, CA - (NewMediaWire) - March 12, 2019 - Aemetis, Inc. (NASDAQ: AMTX) announced that the company will host a conference call to review the release of its fourth quarter and year-end 2018 earnings report:Date: Thursday, March 14, 2019Time: 11 am Pacific Time (PT)Live Participant Dial In (Toll Free): +1(877) 407-8035Live Participant Dial In (International): +1(201) 689-8035Webcast URL: http://www.investorcalendar.com/event/45300Attendees may submit questions during the Q&A portion of the conference call.After March 14th, the webcast will be available on the Company’s website (www.aemetis.com) under Investors/Conference Calls. The voice recording will also be available through March 21, 2019 by dialing (Toll Free) (877) 481-4010 or (International) +1 (919) 882-2331 and entering conference ID number 45300.About AemetisHeadquartered in Cupertino, California, Aemetis is an advanced renewable fuels and biochemicals company focused on the acquisition, development and commercialization of innovative technologies that replace traditional petroleum-based products by the conversion of ethanol and biodiesel plants into advanced biorefineries. Founded in 2006, Aemetis owns and operates a 60 million gallon per year ethanol production facility in California’s Central Valley, near Modesto. Aemetis also owns and operates a 50 million gallon per year renewable chemical and advanced fuel production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin for customers in India, the US and Europe. Aemetis operates a research and development laboratory, and holds a portfolio of patents and related technology licenses for the production of renewable fuels and biochemicals. For additional information about Aemetis, please visit www.aemetis.com.External Investor Relations Contact: Kirin Smith PCG Advisory Group (646) 863-6519 ksmith@pcgadvisory.com Investor Relations/ Media Contact: Todd Waltz (408) 213-0940 investors@aemetis.com

Prodrug of THC Improves Fluid Outflow Across Trabecular Meshwork and Positively Impacts Disease Markers Associated with Glaucoma-Related Fibrosis and InflammationChanges in Neovascularization Markers Indicate Potential Utility of NB1111 in Diabetic Retinopathy and Macular Degeneration Long Beach, CA - (NewMediaWire) - March 12, 2019 - Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on developing bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that data generated by Glauconix Biosciences, Inc. has validated the mechanism of action of NB1111, Nemus’ proprietary prodrug of tetrahydrocannabinol (THC-valine-hemisuccinate, or THCVHS), in lowering intraocular pressure (IOP), a defining symptom of hypertensive glaucoma.The analyses involved a laboratory model using human donor cells that contained the ocular tissue responsible for helping to regulate intraocular pressure, the trabecular meshwork. The studies included a comparison of the activity of tetrahydrocannabinol (THC), the biologically active part of NB1111, in facilitating fluid drainage resulting in lower IOP as well as lowering levels of biomarker molecules associated with inflammation and fibrosis, two processes associated with tissues that are damaged in a disease setting – including glaucoma and other ocular disordersResearchers have previously demonstrated that ocular tissues possess a high degree of cannabinoid receptors, especially on organs that help regulate IOP. Given that THC binds both types of cannabinoid receptors, these data point to a unique mechanism of action whereby the ability of THC to bind to cannabinoid receptors results in a beneficial decline in IOP due to enhanced fluid drainage. When IOP is left unchecked, there is often damage to the optic nerve, leading to irreversible vision loss. Additionally, biomarkers associated with inflammation and fibrosis in tissues affected by glaucoma were significantly decreased, pointing to anti-inflammatory and anti-fibrotic activities that are often associated with the cannabinoid class of molecules in other disease-states. The studies also demonstrated that two biomarkers associated with neovascularization, a process of new blood vessel formation that can lead to vision loss or retinal detachment, were significantly lowered by exposure to THC. Neovascularization is often associated with diabetic retinopathy and macular degeneration, two leading causes of blindness, especially in older adults. “The Glauconix Biosciences’ 3D-HTM™ technology was designed to help accelerate drug development by using bioengineered human donor 3D tissue models for target identification and validation, high throughput screening, and drug efficacy with physiological endpoints, such as fluid outflow,” commented Karen Torrejon, Ph.D., Founder and Chief Scientific Officer of Glauconix. “Historically, our technology has exhibited significant predictive value in assessing a drug candidate’s utility and likelihood of clinical success. Nemus’ data helps to provide a rationale for cannabinoid activity in lowering IOP and indicates a potential for the advancement of NB1111 into clinical testing.” “These studies were significant across a spectrum of findings and we plan on submitting the data to an upcoming major ophthalmology meeting. Micro-quantities of cannabinoid delivered directly into the eye could have the dual benefit of a therapeutic effect while mitigating risk of systemic adverse events through direct tissue targeting, an advantage associated with using bioengineered molecules,” remarked Brian Murphy, MD, CEO and Chief Medical Officer of Nemus. “The impact on markers of ocular neovascularization also reinforces our commitment to test our cannabinoid-based ocular platform of NB1111, the prodrug of THC, and NB2222, the analog of cannabidiol (CBD), in ocular indications beyond glaucoma.”About Glauconix BiosciencesGlauconix Biosciences is a leading developer of ophthalmic ex-vivo dynamic 3D human tissue models for accelerating therapeutic innovation and ...

Seattle, WA - (NewMediaWire) - March 12, 2019 - CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FluroTech Ltd. (TSX-V: TEST) (OTCQB: FLURF). The company recently announced a new proof-of-concept for its advanced cannabis biomarker technology, which enables cultivators, dispensaries, and regulators to easily trace products across the supply chain.The cannabis industry is projected to exceed $146 billion by 2025, according to Grand View Research, driven by the legalization of adult-use and medical cannabis around the world. With the breakneck pace, the industry has faced a number of growing pains along the way. Product recalls, counterfeit products, mislabeled products, and supply chain issues have introduced challenges for growers, dispensaries, consumers, and regulators.Supply Chain ChallengesThe cannabis industry has experienced rapid growth over the past several years, but there have been plenty of growing pains along the way. According to one study, 35 percent of more than 80 cultivars tested had genetics that didn’t match the cultivar being sold. Consumers were buying Sativa cultivars that were advertised as Indica and vice versa. California cannabis labs are also finding toxic metals in vape cartridges, which could cause serious health issues.Counterfeit products have caused other problems. G Pen, a leading high-end portable vaporizer, was awarded $47 million in 2017 after suing more than 60 online retailers selling counterfeit versions of their products. Even worse, some dispensaries were found to be selling fake vape cartridges, which could introduce health risks since the contents of those cartridges are completely unknown and unregulated.“Legal cannabis markets around the world continue to express concern about black market production entering regulated systems,” says FluroTech CEO Danny Dalla-Longa. “Regulators, responsible for consumer protection, have noted an increase in the number of these allegations. Legal growers need to protect their brands and reputation, which we believe creates an expanding market for our technology.”Governments have also struggled to control the supply chain. Without a good way to track legal product, there’s no way for them to ensure that legal cannabis remains out of the black market and black market cannabis remains out of the legal market. Tracking solutions could also enable them to trace cannabis back to its origins for tax collection purposes, as well as to assist with any product recalls that may be issued.Please Click Here to Receive a FluroTech Investor Presentation and Future Updates.Biomarker-based SolutionsDNA biomarkers, short for biological markers, have become a popular way to track everything from clothing to livestock. After applying a spray solution, the DNA acts as a molecule-sized encrypted barcode that can be used to track almost anything across a supply chain. The fashion industry, for example, has used the technology to verify the authenticity of high-end clothing and accessories to combat counterfeit products.The same technology can be applied to the cannabis industry. By bonding to the plant, biomarker technologies can withstand processing and even show up in refined products, such as oils and edibles. Dispensaries, regulators, cultivators and other interested parties can feed the product into a reader to access the unique “encrypted barcode”. This information can be used to confirm the origin, strain, permit or other relevant information.While most conventional biomarking technologies utilize sprays, FluroTech’s CTO Dr. Elmar Prenner doesn’t believe that these will be acceptable under future Health Canada regulations. The company recently announced a proof-of-concept technique that introduces water-based biomarkers through the root system of cannabis and hemp plants, so that the nanoparticles are absorbed throughout all of the plant.Using the company’s cost-effective CompleTest™ equipped with biomarking scopes, these unique ...